Regeneron Pharmaceuticals (REGN) EBITDA (2009 - 2026)

Regeneron Pharmaceuticals has reported EBITDA for 18 years, with the latest figure at $661.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 21.77% year-over-year to $661.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.4 billion (down 4.33% YoY), and the FY2025 full-year result was $4.6 billion, up 2.33% from the prior year.
• EBITDA for Q1 2026 stood at $661.6 million, down from $853.1 million in the prior quarter.
• The five-year high for EBITDA was $1.5 billion in Q3 2025, with the low at $661.6 million in Q1 2026.
• Average EBITDA over 5 years is $1.1 billion, with a median of $952.3 million recorded in 2023.
• Year-over-year, EBITDA sank 74.23% in 2022 and jumped 51.17% in 2024.
• Tracing REGN's EBITDA over 5 years: stood at $1.2 billion in 2022, then climbed by 1.79% to $1.3 billion in 2023, then sank by 32.33% to $849.6 million in 2024, then climbed by 0.41% to $853.1 million in 2025, then retreated by 22.45% to $661.6 million in 2026.
• The last three EBITDA figures came in at $661.6 million (Q1 2026), $853.1 million (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.

Peer Comparison